Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.57 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.46 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | GPR84 | Q9NQS5 | 8/20 | 0.45 |
| ▸ | CA1 | P00915 | 2/20 | 0.45 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | LCK | P06239 | 1/20 | 0.44 |
| ▸ | PPARD | Q03181 | 1/20 | 0.44 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.44 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.44 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.43 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28301190 | 0.92 | CA2 (0.53) | CA2GRIK1GRIK2TSHRGPR84 | |
| Dimethylamine SCHEMBL28441468 | 0.85 | CA2 (0.44) | CA2GRIK1GRIK2TSHRGPR84 | |
| SCHEMBL9718047 | 0.82 | LCK (0.47) | CA2TSHRGPR84CA1FFAR1 | |
| SCHEMBL9132316 | 0.80 | GPR84 (0.52) | CA2GRIK1GRIK2TSHRGPR84 | |
| SCHEMBL28989906 | 0.80 | GRIK1 (0.47) | CA2GRIK1GRIK2TSHRGPR84 | |
| SCHEMBL28989917 | 0.80 | GRIK1 (0.47) | CA2GRIK1GRIK2TSHRGPR84 | |
| SCHEMBL28989949 | 0.80 | GRIK1 (0.47) | CA2GRIK1GRIK2TSHRGPR84 | |
| SCHEMBL28989897 | 0.80 | GRIK1 (0.47) | CA2GRIK1GRIK2TSHRGPR84 | |
| SCHEMBL9332419 | 0.78 | CA2 (0.59) | CA2GRIK1GRIK2GPR84CA1 | |
| SCHEMBL8950093 | 0.78 | CA2 (0.59) | CA2GRIK1GRIK2GPR84CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170136048-A1 | COMPOSITIONS AND METHODS FOR THE PRODUCTION OF PYRIMIDINE AND PYRIDINE COMPOUNDS WITH BTK INHIBITORY ACTIVITY | MERCK PATENT GMBH (DE) | 2017-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170136048-A1 | COMPOSITIONS AND METHODS FOR THE PRODUCTION OF PYRIMIDINE AND PYRIDINE COMPOUNDS WITH BTK INHIBITORY ACTIVITY | BTK, SYK, LCK | CA2 1544/4885GRIK1 1840/4885GRIK2 2532/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.